Reviva Pharmaceuticals Holdings (RVPH) Non-Current Debt (2020)

Reviva Pharmaceuticals Holdings (RVPH) posted Non-Current Debt of $2.0 million for Q4 2020, up 38.6% sequentially from $1.4 million in Q3 2020.

Reviva Pharmaceuticals Holdings (RVPH) Non-Current Debt (2020) Analysis & Trends

Reviva Pharmaceuticals Holdings has reported Non-Current Debt for 1 years, with the latest figure at $2.0 million in Q4 2020.

Quarterly Non-Current Debt changed N/A year-over-year to $2.0 million in Q4 2020, while the trailing twelve-month figure through Nov 2020 was $2.0 million (changed N/A YoY) and the FY2020 annual result came in at $750000.0, changed N/A from the prior year.
Non-Current Debt climbed to $2.0 million in Q4 2020 per RVPH's latest filing, from $1.4 million in the prior quarter.
Over five years, Non-Current Debt peaked at $2.0 million in Q4 2020 and troughed at $750000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Reviva Pharmaceuticals Holdings	6.74 Mn	6.74 Mn	-	-

Download Data